The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $478.12, a high ...

Vertex halts VX-264 trials after missing efficacy goals but continues advancing zimislecel, a potential treatment for severe ...

ICER's evaluation of Vertex Pharmaceuticals' non-opioid pain drug, Journavx, finds cost-effectiveness related to potential ...

Despite a $400 million impairment charge, analysts say the removal of a drug-device combo from its portfolio is not a huge ...

Vertex continues to develop type 1 diabetes therapy, zimislecel, which is being investigated in a Phase III trial.

Vertex is ending work on one of its two clinical-stage islet cell treatments after the diabetes therapy looked unlikely to ...

Vertex Software faces strong competition and slower growth, leading to a neutral rating. See why VERX stock remains pricey ...

This is the unique (3,7)-cage, meaning a graph such that each vertex has 3 neighbors and the shortest cycle has length 7.

Back in my glory days (read: high school, two years ago), the SAT was an ancient ritual involving #2 pencils ... I would still be able to do basic algebra. At this point, I started to deeply ...

After just over a month of release, the Chinese mega-hit Ne Zha 2 has passed the $2 billion mark at the global box office. More precisely, it took just 33 days to achieve this unprecedented feat.